Financial Performance - For the year ended December 31, 2023, the company reported revenue of RMB 2,376,487 thousand, representing a 4.8% increase from RMB 2,267,971 thousand in 2022[2] - Gross profit for the same period was RMB 979,393 thousand, a decrease of 9.4% compared to RMB 1,081,428 thousand in the previous year[2] - Net profit for the year was RMB 391,553 thousand, down 63.5% from RMB 1,073,200 thousand in 2022[2] - The profit attributable to equity shareholders of the company was RMB 396,993 thousand, a decline of 63.0% from RMB 1,074,257 thousand in the prior year[2] - Basic earnings per share for 2023 were RMB 0.53, down from RMB 1.44 in 2022[5] - The company reported a significant decrease in operating profit to RMB 513,162 thousand, down from RMB 1,246,275 thousand in the previous year[3] - The total operating expenses for 2023 were RMB 634,133,000, compared to RMB 558,665,000 in 2022, reflecting an increase of 13.5%[24] - The company's net profit decreased by 63.5% from RMB 1,073.2 million for the year ended December 31, 2022, to RMB 391.6 million for the year ended December 31, 2023, with a net profit margin dropping from 47.3% to 16.5%[68] - Gross profit fell by 9.4% from RMB 1,081.4 million to RMB 979.4 million due to intensified market competition[68] Revenue Breakdown - Non-clinical research services generated revenue of RMB 2,308,999,000 in 2023, compared to RMB 2,213,598,000 in 2022, indicating a growth of about 4.3%[13] - Clinical trial and related services revenue increased to RMB 63,424,000 in 2023 from RMB 49,568,000 in 2022, reflecting a growth of approximately 27.8%[13] - Revenue from external customers in China decreased to RMB 1,797,730,000 in 2023 from RMB 1,885,205,000 in 2022, representing a decline of 4.6%[20] - Revenue from external customers in the United States increased significantly to RMB 566,271,000 in 2023, up 58.5% from RMB 356,892,000 in 2022[20] Assets and Liabilities - The company's total assets as of December 31, 2023, were RMB 8,559,794 thousand, slightly up from RMB 8,519,954 thousand in 2022[6] - The net asset attributable to equity shareholders was RMB 8,279,316 thousand, an increase of 1.2% from RMB 8,183,701 thousand in the previous year[2] - As of December 31, 2023, the cash and cash equivalents were RMB 2,862.9 million, a decrease of 1.8% from RMB 2,916.8 million as of December 31, 2022[70] - The equity-to-debt ratio decreased to 17.4% as of December 31, 2023, from 21.0% as of December 31, 2022, mainly due to a reduction in contract liabilities[71] Research and Development - Research and development expenses increased to RMB 96,854 thousand from RMB 77,985 thousand in 2022, reflecting a focus on innovation[3] - R&D expenses for the year ended December 31, 2023, were RMB 96.9 million, a 24.2% increase from RMB 78.0 million in the previous year, reflecting continued investment in R&D[65] Dividends and Shareholder Returns - Proposed final cash dividend per ordinary share for 2023 is RMB 0.16, down from RMB 0.40 in 2022, totaling RMB 119,977 thousand compared to RMB 214,258 thousand in 2022[30] - Final cash dividend approved and paid for the previous fiscal year was RMB 0.40 per ordinary share, totaling RMB 214,244 thousand, an increase from RMB 137,363 thousand in 2022[31] Operational Developments - The company aims to expand its market presence and enhance its service offerings in the contract research organization sector[8] - The company has implemented organizational restructuring to enhance management efficiency and support business development needs[39] - The construction of the Suzhou Phase II facility, covering 20,000 square meters, has been completed, enhancing the company's business throughput and supporting future growth[40] - A new 22,000 square meter supporting facility in Suzhou is under construction, expected to be completed and gradually put into use by 2024[40] Strategic Goals and Future Plans - The company aims to enhance its market share and international influence in the non-clinical pharmacology and toxicology evaluation business while expanding upstream and downstream capabilities[73] - Plans for 2024 include improving pharmacology and toxicology research capabilities and enhancing project management efficiency[74] - The company intends to actively recruit industry experts with overseas experience to strengthen its domestic team's international business capabilities[75] - The company plans to implement stock incentive programs to support its strategic goals and enhance employee motivation and productivity[75] Compliance and Audit - The audit committee has reviewed the financial statements for the year ending December 31, 2023, and confirmed compliance with relevant accounting standards and regulations[96] - The auditors, KPMG, have agreed that the financial figures in the preliminary announcement align with the audited consolidated financial statements for the year[97]
昭衍新药(06127) - 2023 - 年度业绩